Cellectis Anticipates Submitting Multiple Undisclosed INDs Within 12 Months; No Clinical Updates for 3 UCART Programs; Cellectis Q4 2020 Earnings Call Summary
On Friday, March 5, Cellectis held their Q4 2020 earnings call (press release / no slides presented). Cellectis commented on their 3 ongoing clinical trials and the anticipated submission of multiple INDs for undisclosed CAR-T products within the next 12 months. Of note, management outlined their strategic approach to cell therapy development and licensing. Below, Celltelligence provides insights on Cellectis’s strategic approach to collaborations and manufacturing.